Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiolabeled antitumor agents.

D A Goodwin, C F Meares

    Seminars in Nuclear Medicine
    |October 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Researchers explored radiolabeled bleomycin for tumor imaging, finding in vitro data unreliable for predicting in vivo behavior. A better radionuclide is needed due to 57Co-bleomycin

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Enhancement of skin penetration of nonsteroidal anti-inflammatory drugs from extemporaneously compounded topical-gel formulations.

    International journal of pharmaceutical compounding·2013
    Same author

    Pathological implications of iNOS expression in central white matter: an ex vivo study of optic nerves from rats with experimental allergic encephalomyelitis.

    The European journal of neuroscience·2005
    Same author

    Advances in pretargeting biotechnology.

    Biotechnology advances·2003
    Same author

    Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve.

    Neuroscience·2002
    Same author

    Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition.

    Molecular pharmacology·2001
    Same author

    Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.

    Clinical lymphoma·2001
    Same journal

    The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

    Seminars in nuclear medicine·2026
    Same journal

    Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

    Seminars in nuclear medicine·2026
    Same journal

    <sup>18</sup>F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.

    Seminars in nuclear medicine·2026
    Same journal

    Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer.

    Seminars in nuclear medicine·2026
    Same journal

    The role of cardiac PET imaging in cardiac amyloidosis.

    Seminars in nuclear medicine·2026
    Same journal

    PET imaging of large-vessel vasculitis: advancements and future trends.

    Seminars in nuclear medicine·2026
    See all related articles

    Area of Science:

    • Radiopharmaceutical development
    • Nuclear medicine
    • Oncology

    Background:

    • Bleomycin is a model compound for developing radiopharmaceuticals for tumor imaging.
    • In vitro studies often fail to predict the in vivo behavior of radiolabeled drugs.
    • Metal chelation is a viable labeling technique for bleomycin.

    Purpose of the Study:

    • To evaluate properties of various radiolabeled bleomycins for tumor imaging.
    • To identify limitations of current radiolabeled bleomycins.
    • To explore potential for improved radiopharmaceuticals.

    Main Methods:

    • In vitro and in vivo studies of bleomycin labeled with different radionuclides.
    • Chromatographic analysis of radiolabeled bleomycin stability.

    Related Experiment Videos

  • Assessment of biologic behavior in humans.

    • Main Results:

    • In vitro stability does not correlate with in vivo stability, particularly in the presence of serum transferrin.
    • 57Co-bleomycin shows good biologic characteristics but its long half-life causes contamination issues.
    • Radionuclides of elements forming stable bleomycin chelates (Co, Cu, Zn, Ni) lack ideal physical properties for scanning.

    Conclusions:

    • Predicting radiopharmaceutical performance requires in vivo data.
    • 57Co-bleomycin's long half-life limits its clinical utility.
    • Development of a new radionuclide-labeled bleomycin with optimal biologic and physical properties is necessary for effective tumor imaging.